unknown by Alexander Tenenbaum et al.
BioMed CentralCardiovascular Diabetology
ssOpen AcceOriginal investigation
Increased prevalence of left ventricular hypertrophy in 
hypertensive women with type 2 diabetes mellitus
Alexander Tenenbaum*1,2, Enrique Z Fisman1,2, Ehud Schwammenthal1,2, 
Yehuda Adler1,2, Michal Benderly2,3, Michael Motro2 and Joseph Shemesh1,2
Address: 1From the Cardiac Rehabilitation Institute, Sheba Medical Center, 52621 Tel-Hashomer, Israel, 2Sackler Faculty of Medicine, Tel-Aviv 
University, 69978 Tel-Aviv, Israel and 3Neufeld Cardiac Research Institute, Sheba Medical Center, 52621 Tel-Hashomer, Israel
Email: Alexander Tenenbaum* - altenen@sheba.health.gov.il; Enrique Z Fisman - zfisman@post.tau.ac.il; 
Ehud Schwammenthal - sehud@post.tau.ac.il; Yehuda Adler - Yehuda.Adler@sheba.health.gov.il; Michal Benderly - bender@post.tau.ac.il; 
Michael Motro - Michael.Motro@sheba.health.gov.il; Joseph Shemesh - dshemesh@netvision.net.il
* Corresponding author    
Diabetes mellitusEchocardiographyHypertensionLeft ventricular hypertrophy
Abstract
Background: Left ventricular hypertrophy (LVH) is a powerful independent risk factor for
cardiovascular morbidity and mortality among hypertensive patients. Data regarding relationships
between diabetes and LVH are controversial and inconclusive, whereas possible gender differences
were not specifically investigated. The goal of this work was to investigate whether gender
differences in left heart structure and mass are present in hypertensive patients with type 2
diabetes.
Methods: Five hundred fifty hypertensive patients with at least one additional cardiovascular risk
factor (314 men and 246 women, age 52 to 81, mean 66 ± 6 years), were enrolled in the present
analysis. In 200 (36%) of them – 108 men and 92 women – type 2 diabetes mellitus was found upon
enrollment. End-diastolic measurements of interventricular septal thickness (IVS), LV internal
diameter, and posterior wall thickness were performed employing two-dimensionally guided M-
mode echocardiograms. LVH was diagnosed when LV mass index (LVMI) was >134 g/m2 in men
and >110 g/m2 in women.
Results: Mean LVMI was significantly higher among diabetic vs. nondiabetic women (112.5 ± 29 vs.
105.6 ± 24, p = 0.03). In addition, diabetic women presented a significantly higher prevalence of
increased IVS thickness, LVMI and left atrial diameter on intra-gender comparisons. The age
adjusted relative risk for increased LVMI in diabetics vs. nondiabetics was 1.47 (95% CI: 1.0–2.2) in
females and only 0.8 (0.5–1.3) in males.
Conclusion: Type 2 diabetes mellitus was associated with a significantly higher prevalence of LVH
and left atrial enlargement in hypertensive women.
Introduction
Patients with overt diabetes and hypertension are exposed
to an exceptionally high risk of cardiovascular death, and
are generally thought to need a more intensive risk factor
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ventricular hypertrophy (LVH) is the most powerful inde-
pendent risk factor for cardiovascular morbidity and mor-
tality in these patients. The prevalence of LVH in patients
with essential hypertension is in average 40% (range 12%
to 70%), depending to a large extent on the measurement
technique used [2-6]. The relationships between glucose
metabolism abnormalities and LVH have been described
in several reports [7-10]. However, the findings were con-
troversial and inconclusive [11]. The gender differences
were not specifically investigated in this issue. The goal of
this work was to elucidate whether gender differences in
left heart structure and mass are present in hypertensive
patients with type 2 diabetes.
Patients and methods
The International Nifedipine GITS Study of Intervention
as a Goal in Hypertension Treatment (INSIGHT) Trial has
studied hypertensive patients with at least one additional
cardiovascular risk factor and thus with a clear-cut eleva-
tion in overall risk. The design of the INSIGHT study has
been described elsewhere [12,13]. The INSIGHT trial has
also conducted a number of side arms in different coun-
tries to address several important issues for which infor-
mation is still limited.
Over the course of 18 months 585 high risk patients with
hypertension plus at least one additional risk factor who
were recruited to the INSIGHT study in our region under-
went echo-Doppler examination. A total of 25 patients
dropped out during the recruitment because of the techni-
cal reasons (suboptimal echocardiographic images. There-
fore, 560 patients (314 men and 246 women, age 52 to
81, mean 66 ± 6 years), were enrolled in the present anal-
ysis. In 200 (36%) of them – 108 men and 92 women –
type 2 diabetes mellitus found upon enrollment (preva-
lent diabetes group). The remaining 360 patients without
clinically manifested diabetes constituted the nondiabetic
group.
The diagnosis of diabetes was made on the basis of the
reported history and medical records.
Coronary artery disease (CAD) was diagnosed in accord-
ance with the INSIGHT clinical trial protocol: docu-
mented previous myocardial infarction, obstruction equal
or more than 70% in at least one of the major epicardial
arteries on coronary angiography, percutaneous transcor-
onary angioplasty or coronary artery bypass grafting, and
based on accepted reliable medical records (hospitaliza-
tion summary and/or coronary angiography protocol.
Echo-Doppler-two dimensional echocardiography
Examinations were performed at baseline with a Hewlett-
Packard ultrasound imaging system model SONOS 1000,
1500 or 2500 with a 2.5 and 3.5 Mhz transducer. Standard
images were obtained from the left parasternal (long and
short axis view), apical (long, two chamber and four
chamber) and subcostal views.
Two-dimensionally guided M-mode echocardiograms of
the left ventricle (LV) were taken at cordal level, with the
patient in partial left decubitus position, and three to five
measurements were averaged. End-diastolic measure-
ments of interventricular septal thickness (IVS), LV inter-
nal diameter, and posterior wall thickness (PWT) were
carried out in accordance with the American Society of
Echocardiography recommendations.[14] The left ven-
tricular mass (LVM) was calculated by the formula intro-
duced by Devereux and Reicheck [15] and was indexed for
body surface area to obtain the LVM index (LVMI). Left
ventricular hypertrophy was diagnosed when LVMI was
>134 g/m2 in men and >110 g/m2 in women [16]. Only
frames with optimal visualization of interfaces and show-
ing the septum, LV internal diameter and posterior wall
simultaneously were used for reading
All studies were recorded on a super-VHS tape and evalu-
ated by 2 cardiologists with expertise in echocardiogra-
phy, who were blinded to the presence or absence of
diabetes. In case of disagreement, a third examiner was
consulted
Statistical analysis
Data were analyzed using SAS software [17]. Comparisons
of proportions were made using the chi-square test. Statis-
tical analysis for inter- and intra-gender comparisons was
performed using the Student's t test. A p value of less than
0.05 was considered statistically significant.
Results
In inter-gender comparisons, men were older; the preva-
lence of smoking and proven CAD was significantly
higher among them. Duration of hypertension was longer
among women (Table 1). No inter-gender differences
were found regarding systolic and diastolic blood pres-
sures on inclusion. In patients of both genders (intra-gen-
der comparisons) no differences were found regarding
age, systolic and diastolic blood pressures on inclusion,
duration of hypertension and prevalence of CAD. How-
ever, mean LVMI was significantly higher among diabetic
women (112.5 ± 29 vs 105.6 ± 24, p = 0.03). Only among
diabetic women a significantly higher prevalence of
increased IVS thickness, LVMI and left atrial diameter was
found on intra-gender comparisons (Table 2, Figures 1, 2,
3). The age adjusted relative risk for increased LVMI in dia-
betics vs nondiabetics was 1.47 (95% CI: 1.0–2.2) in
females and only 0.8 (0.5–1.3) in males.Page 2 of 5
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In the present study diabetes mellitus was associated with
increased prevalence of LVH (in terms of increased LVMI
and IVS) in hypertensive women. LVH is more than just
an adaptive response to hypertension. It is predictor a
poor prognosis, independently of blood pressure levels.
In the Framingham, the relative risk of cardiovascular
mortality for every 50 g increment in echo LV mass was
1.73 in men and 2.12 in women, even after correction for
risk factors such as blood pressure [2]. In patients with
established CAD, the extra risk for cardiac death due to
LVH is 2.8, when adjusted for age, gender and hyperten-
sion [3]. In these patients, this extra risk due to echo LVH
appears to be greater than that for multivessel coronary
disease or to LV dysfunction.
Recently, the close relationship between glucose metabo-
lism abnormalities and other cardiovascular risk factors
and diseases was emphasized [18-20]. In a previous study,
LVH was present in 31% of diabetics, and systolic blood
pressure was of no value in identifying those diabetics
who had LVH [21], possibly because insulin resistance
itself stimulates LVM growth [22]. Verdecchia et al. sup-
posed that in addition to circulating insulin, insulin
growth factor-1 is also an independent determinant of
LVM and geometry in essential hypertension [9]. How-
ever, Galvin et al. concluded that insulin resistance and
hyperinsulinemia are not independent predictors of left
ventricular mass in humans [11]. In a relatively healthy,
population-based sample of hypertensive adults, type 2
diabetes was associated with higher LVM, more concentric
LV geometry, and lower myocardial function, independ-
ently of age, sex, body size, and arterial blood pressure
[10]. In the present study, similarly to Framingham cohort
[23], diabetes was associated with higher LV mass in
women but not in men. In addition, the prevalence of
patients with increased left atrium diameter was signifi-
cantly higher among diabetic women. We assumed that
the latter phenomenon may be associated with increasing
left atrial filling pressure following more pronounced
LVH-related diastolic dysfunction.
It is well established that diabetic women present a greater
risk for cardiovascular morbidity and mortality compared
Table 1: Baseline characteristics of the study population: number (%) or mean ± standard deviation
MEN WOMEN
Variables Non DM T2DM Non DM T2DM
n = 206 n = 108 n = 154 n = 92
Age (years) 65.8 ± 6.2 65.9 ± 5.6 60.0 ± 6.9 61.0 ± 6.2
Weight (kg) 80.7 ± 13 82.3 ± 13.2 76.0 ± 12.4 76.7 ± 13.2
HTN duration 10.7 ± 8.8 10.7 ± 8.7 12.3 ± 9.4 14.8.0 ± 9.4
Prevalent CAD 49 (25) 22 (21) 13 (8) 11 (12)
Current smokers 50 (25) 14 (13) 18 (11) 8 (9)
SBP (mm Hg) 170 ± 21 174 ± 19 170 ± 18 173.6 ± 23
DBP (mm Hg) 95.2 ± 12 95 ± 9.8 94.8 ± 9.6 92.1 ± 11.3
LVMI (g/m2) 119.4 ± 30 116.5 ± 26 105.6 ± 24 112.5 ± 29*
SBP, DBP – systolic and diastolic blood pressures on inclusion; CAD – coronary artery disease; HTN duration-duration of hypertension (years); 
T2DM – type 2 diabetes mellitus; * p < 0.05.
Table 2: Echocardiographic data in study patients
MEN WOMEN
Variables Non DM T2DM Non DM T2DM
n = 206 n = 108 n = 154 n = 92
IVS ≥ 12 mm 123 (60) 66 (61) 63 (41) 51 (56)*
PW ≥ 12 mm 36 (17) 17 (16) 13(8) 12 (13)
Increased LVMI 55 (27) 21 (19) 53 (35) 45 (49)*
LA ≥ 40 mm 100 (49) 60 (56) 42 (27) 40 (44)**
*p < 0.05, **p < 0.001; IVS = interventricular septum, PW = posterior wall, LVMI = LV mass index >I 10 (female) and >134 gr/m2(male); LA = left 
atrial diameter; T2DM – type 2 diabetes mellitus. Data are number (%) of patients.Page 3 of 5
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findings could represent an important component of the
underlying mechanism.
Whether diabetes is associated with changes in left heart
structure independently of blood pressure and metabolic
abnormalities remains to be elucidated in large prospec-
tive population-based studies.
Conclusion
Type 2 diabetes mellitus was associated with a signifi-
cantly higher prevalence of LVH and left atrial enlarge-
ment in hypertensive women.
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Gender differences in increased left ventricular mass index (LVMI) preval  (percent)Figure 1
Gender differences in increased left ventricular mass index 
(LVMI) prevalence (percent). Diabetic women present a 
larger LVMI than nondiabetic women, while opposite results 
are seen in men.
Gender differences in increased interventricular septal thick-ness (IVS) prevalence (pe cent)Figure 2
Gender differences in increased interventricular septal thick-
ness (IVS) prevalence (percent). Both diabetic women and 
diabetic men present a larger IVS than their nondiabetic 
counterparts, but differences are significant only for women.
Gender differences in increased left atrial (LA) prevalence (p rc nt)Figure 3
Gender differences in increased left atrial (LA) prevalence 
(percent). Both diabetic women and diabetic men present a 
larger LA than their nondiabetic counterparts, but differ-
ences are significant only for women.Page 4 of 5
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